## P<sub>0</sub>4

## Novel and highly selective inhibitors of Fibroblast activation protein (FAP)

✓ FAP: Serine protease

Target in oncology

Talabostat, failed in phase II trials

✓ Problem to solve: Talabostat is not selective => side effects?

Selective inhibitor needed to validate FAP

as target in oncology and other disease areas

✓ Poster presentation:

The first selective and potent FAP inhibitor with drug-like properties!

✓ ADDN: Antwerp Drug Discovery Network

@ University of Antwerp

=> (Serine) protease research platform



www.addn.be

Jansen K. et al.